Gapping up
In reaction to earnings/guidance:
- GME +47.9%, OLLI +7.9%, HQY +6.4%, GBX +5% (guidance), WGO +4.7%, SON +2.3%, EPAC +1.1%
Other news:
- ETNB +51.4% (Phase 2b ENLIVEN Trial of Pegozafermin in Nonalcoholic Steatohepatitis (NASH) Achieved High Statistical Significance on Both Primary Histology Endpoints with Weekly (QW) and Every-Two-Week (Q2W) Dosing at 24 Weeks)
- SMLR +13.2% (CEO to step dow names new CEO)
- AVDL +8.1% (FDA has approved its Pre-Launch Activities Importation Requests (PLAIR) for LUMRYZ)
- KFS +6.4% (authorizes new $10 mln share repurchase program)
- SSYS +4.8% (Board of Directors unanimously rejects unsolicited proposal from Nano Dimension (NNDM))
- KRTX +3.5% (prices offering of 2479391 shares of its common stock at $161.33 per share)
- NIO +3.1% (very confident that it will hit sales goal according to Bloomberg interview)
- EFC +1.4% (authorizes new $50 mln share repurchase program)
- FG +1.1% (authorizes new $25 mln share repurchase program)
Analyst comments:
- SMTC +3.4% (upgraded to Buy from Neutral at B. Riley Securities)
- DNUT +2.6% (upgraded to Buy from Hold at Truist)
- KNX +2.3% (upgraded to Outperform from Peer Perform at Wolfe Research)
- ENPH +1.4% (upgraded to Positive from Neutral at Susquehanna)
- PHM +1.1% (upgraded to Outperform from Peer Perform at Wolfe Research)